fda bpc 157 compounding category 2 list 1 vs. Category 2. The FDA's peptide update, explained. Category peptides are on the FDA's “difficult to compound” list, which effectively blocks licensed pharmacies from producing them. Category 1 means Regulatory Alert: FDA's April 2026
Regulatory Alert: FDA's April 2026 Update on BPC 157 and GHK Cu Holt Law The FDA's Category 2 list restricted 19 peptides from compounding. Now, approximately 14 of them may be coming back. HHS has signaled that peptides previously barred from compounding spanning categories like You may have heard buzz about 14 peptides potentially returning to legal compounding. Here's what we know: HHS Secretary RFK Jr. stated his intention to move these peptides from FDA Category 2 FDA mulls compounding for peptides previously flagged over safety risks BioSpace Industry Update: Interim 503A and 503B Bulks Lists New Revisions
Pay in 4 interest-free payments of $6.00 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10


